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Bacterial protein secretion - a target for new antibiotics? 
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The heavy use of antibiotics over recent decades has 
resulted in widespread resistance of bacteria to many 
drugs. Overcoming resistance requires new approaches 
to antibiotic development, including the exploitation of 
new targets in the bacterial cell. Protein secretion is 
essential for bacterial cell growth and virulence, so it 
could be a suitable target for new therapeutic agents. 
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The first ‘miracle drugs’, the sulfonamides and penicillins, 
were introduced in the late 1930s and the 1940s to subdue 
bacterial pathogens. It was commonly believed that the use 
of this type of drug could soon lead to the permanent 
control of bacterial disease. That optimism now seems sadly 
naive. Although morbidity and mortality from bacterial dis- 
eases are nruch lower than in the pre-antibiotic era, bacter- 
ial diseases still kill tens of thousands of people in the 
United States each year and remain the major cause of 
death in underdeveloped nations. Microorganisms have sur- 
vived billions of years through rapid adaptation and evolu- 
tion, and the intense selective pressure exerted globally by 
the heavy use of antibiotics has led to widespread dissemi- 
nation of resistance mechanisms among common pathogens 
[l]. Drug-resistant bacterial strains for which there are few 
chemotherapeutic options are a particular danger in institu- 
tional settings (e.g. hospitals and nursing homes) where 
there are large populations of immunocompromised indi- 
viduals, such as those with AIDS. There is an urgent need 
for new antimicrobial drugs to address these challenges. 
Antibiotics that are currently in widespread clinical use 
target diverse cellular processes such as protein synthesis 
(targeted by the aminoglycosides, tetracyclines and 
macrolides), cell-wall synthesis (p lactams and glycopep- 
tides), DNA supercoiling (quinolones) and folate synthe- 
sis (sulfonamides). The antibiotics introduced to clinical 
practice in the past 20 years have been almost exclusively 
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structural variants of members of established drug fami- 
lies. The newer variants generally have improved efficacy 
or have broader action spectra than established drugs, or 
are able to overcome some resistance mechanisms. 
Although this approach to drug development has been 
reasonably successful, microbes have made their ability to 
evolve resistance to each new modification abundantly 
clear. Consider the situation with antibiotics that are 
inhibitors of cell-wall synthesis. Clinical isolates of peni- 
cillin-resistant Streptococcus pneumoniae, the most frequent 
cause of bacterial pneumonia, increased 60-fold in the 
United States in 1987-1992 [Z]. Hospital-acquired infec- 
tions with methicillin-resistant Staphylococcw and van- 
comycin-resistant Enterococcus have increased dramatically 
worldwide [3]. These observations suggest that identify- 
ing completely new classes of antimicrobial compounds 
which act on new targets may be necessary to cope with 
pathogens in the future [4]. A potential target within the 
bacterial cell should be essential for cell survival or 
growth, and should be broadly distributed and highly con- 
served in bacteria but not in humans. Alternatively, func- 
tions that are necessary only for pathogenic behavior could 
be targeted. To illustrate the type of physiological 
processes that fit these criteria, we will focus on the export 
of proteins across cellular membranes. 
The pathways of bacterial protein secretion 
Cells interface with their environment through proteins 
that are displayed on, or translocated through, the cyto- 
plasmic membrane. Functions that rely on extra-cytoplas- 
mic proteins include nutrient uptake, chemosensing, 
motility, adhesion and cell-wall biosynthesis. Roughly one 
fifth of the proteins in the average bacterial cell are 
located partially or completely outside the cytoplasmic 
membrane [S]; the ability to localize these proteins is 
essential for growth and viability. As purified phospho- 
lipid membranes are impermeable to polar, charged poly- 
mers such as proteins, the most fundamental issue in 
protein export is to understand how the hydrophobic inte- 
rior of the lipid bilayer is traversed. Most extra-cytoplas- 
mic proteins initially have an amino-terminal signal 
peptide of 20-30 residues and cross the cytoplasmic mem- 
brane via the general secretory pathway (GSP) [5,6]. The 
GSP has been studied most extensively in Eschericha co/i, 
a gram-negative bacterium; bacteria of this class have a 
physically distinct outer membrane surrounding the cyto- 
plasmic membrane. The two membranes are separated by 
a thin peptidoglycan layer and a compartment called the 
periplasm. The GSP of gram-negative bacteria is responsi- 
ble for translocating proteins into the periplasm; other 
mechanisms are then required for crossing the outer 
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Protein-secretion pathways of the outer and 
inner (cytoplasmic) membranes of gram- 
negative bacteria. (a) An outline of the general 
protein-secretion pathway off. co/i. SecA 
binds to the amino-terminal signal peptide of 
preproteins as they are translated. In the 
presence of ATP, SecA is able to associate 
with the membrane-pore complex, SecE-SecY, 
and to partially insert into the membrane, 
allowing the hydrophobic region of the signal 
peptide to insert. The remainder of the 
preprotein is then threaded through the 
SecE-SecY pore. The membrane-associated 
leader peptidase (Lep) cleaves the signal 
peptide, releasing the mature protein into the 
periplasm. ATP hydrolysis allows SecA to be 
released from the membrane complex to 
recycle. A more complete description of the E. 
co/i GSP can be found in [6]. (b) Two 
supplementary pathways used by gram- 
negative bacteria for outer-membrane export of 
proteins that have been delivered to the 
periplasm by the GSP See references [5] and 
[211 and text for details. 
membrane (see below). In contrast, gram-positive bacteria 
lack an outer membrane so the GSP is sufficient for the 
release of proteins from the cell. 
The core of the GSP in E. co/i consists of three proteins - 
SecA, SecE and SecY - each of which is necessary for 
viability and for reconstitution of protein secretion in a&-o 
[5,6]. A simplified outline of the E. co/i GSP is shown in 
Figure la. SecA binds to the signal peptide of a preprotein 
as it exits the ribosome [7,8]. SecA then partially inserts 
into the cell membrane, driving the signal peptide into the 
membrane at or near a pore comprised of SecE and SecY 
[9,10]. SecA is an ATPase, and ATP binding and hydroly- 
sis stimulate the insertion and release of SecA from the 
SecE-SecY membrane-pore complex [ 1 l-131. The pore, 
the structure of which has not yet been determined, facili- 
tates the passage of export-competent (i.e. non-folded) 
preproteins through the membrane. Translocation of pre- 
proteins appears to be driven across the membrane by 
energy derived from SecA-mediated ATP hydrolysis and 
the transmembrane proton gradient [14]. ATP hydrolysis 
is clearly involved early in the process and can suffice for 
translocation in vitro but a transmembrane proton gradient 
dramatically increases the rate of translocation in vitro and 
is necessary for secretion in v&o [15]. As the preprotein 
crosses the membrane, the signal peptide is cleaved by a 
peptidase (leader peptidase) located on the outer face of 
the membrane. Signal-peptide cleavage is not required for 
membrane translocation per se but E. coli strains lacking 
leader peptidase die quickly, presumably because an 
uncleaved signal-peptide anchor interferes with the 
function of essential extra-cytoplasmic proteins [ 161. 
Secreted proteins are often important pathogenic ‘viru- 
lence factors’ that are intimately involved in host coloniza- 
tion [17]. Cholera toxin, diptheria toxin and tetanus toxin 
are well-known examples of secreted bacterial virulence 
factors. These proteins are typically not necessary for 
growth of the pathogen outside the host organism [l&19]. 
Secreted virulence factors, like cell-surface proteins, have 
often been used or proposed as vaccine antigens; less 
appreciated, however, is the possibility that the systems 
used for virulence-factor secretion could be targets for 
therapeutic agents to prevent colonization or aid in clear- 
ance of specific pathogens. Some virulence factors, such as 
the Neisseria gonodoeae IgA protease, are released into the 
periplasm by the GSP and subsequently cross the outer 
membrane without assistance from any additional secre- 
tory system [ZO]. More commonly, specialized outer-mem- 
brane channels facilitate the release of periplasmic 
intermediates (Figure lb). One such system is used for 
the assembly of pili in enteric bacteria [Zl]. Pili are fibrous 
structures extending from the cell surface that are used for 
attachment to host cells. Another pathway (often termed 
type II) is used by the plant pathogen Err&ma for secre- 
tion of the enzymes pectate lyase and cellulase which are 
used in plant-cell-wall degradation; this pathway is also 
used by the mammalian pathogen Pseudomonas aemginosa 
to secrete cytotoxin A, lipases and proteases [5]. 
Some secreted proteins cannot start their journey via the 
GSP because they lack an amino-terminal signal peptide. 
These proteins use alternative secretory pathways to tra- 
verse the gram-negative cell envelope (Figure 2). The alter- 
native pathways include the type I secretory, pathways, 
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Figure 2 
Non-GSP-dependent protein-secretion 
pathways of gram-negative bacteria. The type 
I and type Ill secretory pathways are shown. 
The ATPase component (the ABC transporter; 
purple) of the type I pathway is located in the 
cytoplasmic (inner) membrane and recognizes 
substrates vra a carboxy-terminal recognition 
sequence. Substrates of the type I pathway 
cross the entire envelope in a single step via 
the ABC transporter, periplasmic linker (light 
orange) and outer-membrane pore (green) so 
there is no free periplasmic intermediate. The 
cytoplasmic membrane component of the type 
Ill pathway (yellow) is probably composed of 
several subunits. Type Ill pathways have a 
cytoplasmic ATPase subunit that is thought to 
recognize substrates via a signal located at or 
near the amino terminus. 
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which have three major components - an inner-membrane 
channel, a periplasmic linker and an outer-membrane pore 
[Z?]. Proteins secreted by type I pathways have a non-cleav- 
able carboxy-terminal secretion signal which is recognized a 
protein of the inner membrane. This inner-membrane 
protein has an ATP-binding cassette that is characteristic of 
a large family of membrane proteins called ABC trans- 
porters [23]. These transporters are widely distributed in 
both prokaryotes and eukaryotes, and are involved in 
processes as diverse as sugar uptake (the maltose trans- 
porter in E. co/i), antigenic peptide transport (the TAP 
transporter in the endoplasmic reticulum of human lympho- 
cytes) and drug efflux (the mammalian multidrug resistance 
protein). How the ABC-transporter protein of type I protein 
secretion systems couples ATP hydrolysis to the transloca- 
tion of substrates across the inner membrane is unknown 
but, as with the GSP, the trdnsmembrane proton motive 
force is also required for secretion [24]. It has been pro- 
posed that translocation of proteins by type I secretory 
pathways across both membranes of the Gram-negative cell 
envelope is a concerted process [24]. 
A second non-GSP-dependent secretory pathway is the 
‘type III’ pathway that is used by some gram-negative 
pathogens to inject virulence factors directly into rnam- 
malian cells [ZS]. For example, this type of pathway is 
involved in the secretion of antiphagocytic proteins by 
YerSinia species (including Yersinia p&s, the agent of 
bubonic plague), and in the secretion of host-cell invasion 
factors by bacteria of the enteric pathogenic genera Shigel’r’a 
and Sa/mmoneh’a [25]. This type III pathway is more complex 
than the type I pathway; it includes a cytoplasmic ATPase, 
seven probable inner-membrane proteins and at least one 
outer-membrane protein. The outer-membrane component 
is homologous to the outer-membrane channel of the type 
II pathway (Figure 1) [26], and is therefore an attractive 
target for inhibitors that could block two distinct secretory 
pathways without ever crossing the cytoplasmic membrane. 
The secretion of the protein subunits that are used to build 
the bacterial flagellum also depends on a type III pathway. 
The bacterial flagellum acts as a screw propeller that drives 
cells through aqueous environments [27,28]. The majority 
of eubacterial species can build flagella, so the flagellar 
secretory system is widely distributed. Flagellar assembly 
and function often have an important role in bacterial infec- 
tions, because many pathogens require motility for host col- 
onization [29]. The flagellum is assembled outwards from 
the cytoplasmic membrane [30]; subunits are secreted via a 
gated type III channel thought to be located in the center 
of the ring at the base of the flagellum [28] (Figure 2). 
Secreted subunits pass through a central channel in the 
growing axial structure(s) to be assembled at the tip. 
Because subunits traverse the outer-membrane via the axial 
channel, there is no need for the separate outer-membrane 
channel found in other secretory pathways. 
Bacterial pathogens have clearly evolved diverse attack 
strategies involving secreted virulence factors [17]. Drugs 
targctmg secretory pathways other than the GYP would be 
suitable primarily for use against gram-negative pathogens, 
but such specialized antimicrobial agents could neverthc- 
less be valuable, as can be illustrated by considering the 
cases of Pseuhnonas aemginma and Helimba~fer pylori. 
t! aeruginosa is an opportunistic pathogen that can cause 
fatal wound and burn infections, and chronically infects the 
lungs of cystic fibrosis patients, eventually resulting in 
death [30]. It is notoriously resistant to standard antibiotics 
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and secretes important virulence factors through all the 
pathways described above. H. pylori colonizes the mucosal 
lining of the stomach, and is the ultimate cause of most 
gastric and duodenal ulcers. Treatment of H. pylori infec- 
tion typically requires a combination of three antibiotics; 
clinical isolates that are resistant to one or more of the com- 
ponent antibiotics have been isolated. The hundreds of 
millions of people infected with H. pylon’ worldwide repre- 
sent a huge market for improved therapeutic agents. The 
importance of protein secretion to H. pylon’ pathogenesis is 
demonstrated by observations that virulence is correlated 
with a unique cluster of genes encoding components of 
multiple secretory pathways [31]; the critical VacA cyto- 
toxin is a secreted protein; and flagellar motility (and hence 
flagellar subunit secretion) is necessary for establishment 
of Helicobucter infection in animal models [32]. Narrow 
spectrum antibiotics targeting I! aeruginosu or H. pyhi 
could have profound effects on human health. 
Developing drugs that inhibit protein secretion 
What are the prospects for developing antimicrobial agents 
that target the GSP? The components of the GSP that 
have relatively defined biochemical activities, such as 
leader peptidase and SecA, may offer the best targets for in 
vitro approaches to drug development. Because the active 
site of leader peptidase is outside the cytoplasmic mem- 
brane, agents directed against this enzyme need not cross 
the membrane to be effective. Leader peptidase is a novel 
type of serine protease [33], and one group of compounds 
that inhibit the catalytic activity of the E. cob enzyme has 
already been described [34]. The structures of SecA and 
leader peptidase have not been solved, so there is no 
opportunity at present for rational drug design. Neverthe- 
less, functional assays can be adapted to high-throughput 
screening for inhibitors. Synthetic chemical libraries, 
natural product libraries and combinatorial chemistry 
could provide a vast array of compounds for testing. 
Two compounds that inhibit SecA function are 
known - sodium azide and phenylethyl alcohol [35,36]; 
azide affects ATPase activity but has little future as an 
antibiotic because of its general toxicity. SecA ATPase 
activity,is insensitive to inhibitors of phosphorylation and 
vacuolar-type ATPases and the F,F, ATPase; if highly 
specific inhibitors of the SecA active site could be identi- 
fied generalized toxicity might be avoidable. The signal 
peptide is involved in several stages of the secretion 
process. Stable peptide analogs might be developed that 
could interfere with the binding of SecA (or the 
SecE-SecY complex, or even the leader peptidase) to the 
natural signal peptides of preproteins. 
As the core components of the GSP are known and secre- 
tory activity can be reconstituted using E. co/i GSP compo- 
nents in a defined cell-free system, there is the potential to 
use this assay to identify secretion inhibitors. Alternatively, 
screening strategies have been proposed that use intact E. 
co/i cells which have been genetically engineered to show 
inhibition of GSP activity or which may be used to posi- 
tively select for compounds that reduce secretion [37]. The 
need for new drugs that are active against gram-positive 
pathogens is especially pressing, so it would probably also 
be useful to develop screens using a well-characterized and 
genetically manageable gram-positive species such as 
Badus subtilis or Staphylococcus aureus. 
Developing approaches that target alternative protein- 
secretion pathways will require a greater understanding of 
the structure and function of these pathways. Essentially, 
the only components for which functions have been tenta- 
tively assigned are the putative outer-membrane channels 
and the proteins with ATP-binding motifs such as the ABC 
transporter of the type I system. What the other conserved 
components of the pathways do is as yet unknown. How are 
the inner- and outer-membrane channels formed and regu- 
lated? Is passage through both membranes a concerted 
process with no periplasmic intermediate? How are secre- 
tion signals in substrate proteins recognized? How are sub- 
strates driven through .membranes? To answer these 
questions, and to develop strategies for blocking protein 
secretion in general, will require a combination of biochem- 
ical and genetic analysis, and an integration of cellular and 
molecular biology. Protein secretion is only one of many 
possible targets for the development of new antibiotics; our 
ability to deal with bacterial diseases in the 21st century 
may depend on the enthusiasm and ingenuity we apply to 
the task of drug development around these novel targets. 
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